Purdue Seeks To Stop Watson's Reformulated Oxy Generic

Law360, New York (April 25, 2012, 4:59 PM EDT) -- Purdue Pharma LP is once again taking Watson Pharmaceuticals Inc. to court over its plans to market generic OxyContin, filing suit Tuesday in New York federal court to block Watson's attempts to replicate a new version of the blockbuster painkiller.

The complaint alleges that Watson’s abbreviated new drug applications for extended release oxycodone hydrochloride tablets infringe Purdue’s patent for a reformulated version of the drug.

The patent in question, U.S. Patent No. 8,114,383, specifically refers to an “abuse-proofed” form of the drug that is coated in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.